Huang Gloria S, Arend Rebecca C, Li Maomi, Gunter Marc J, Chiu Lydia G, Horwitz Susan Band, Goldberg Gary L
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Women's Health, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Am J Obstet Gynecol. 2009 Apr;200(4):457.e1-5. doi: 10.1016/j.ajog.2008.12.012. Epub 2009 Feb 6.
To evaluate the relationship of hormone (estrogen receptor alpha, estrogen receptor beta, progesterone receptor) and growth factor receptor (insulin-like growth factor receptor, human epidermal growth factor receptor 2) expression with disease progression in uterine carcinosarcoma.
Immunohistochemistry was performed on tissue arrays using standard methodology. Differences between groups were evaluated by the Wilcoxon rank-sum test. Interactions between tumor stage and receptor expression were determined by linear trend analysis.
Compared with normal endometrium, carcinosarcomas exhibited low estrogen receptor alpha and progesterone receptor expression (all P < .01), but overexpressed estrogen receptor beta (P = .02). Estrogen receptor beta expression increased in advanced stage disease (P = .02). Insulin-like growth factor receptor expression was lower in carcinosarcoma compared with normal endometrium (P = .01). Human epidermal growth factor receptor 2 expression was elevated and increased with disease progression (P < .01).
In uterine carcinosarcoma, estrogen receptor beta expression is elevated and increases with disease progression, whereas estrogen receptor alpha and progesterone receptor are suppressed. Human epidermal growth factor receptor 2 expression is increased, whereas insulin-like growth factor receptor is lower than in normal endometrium. These data support a potential role for estrogen receptor beta in disease progression via crosstalk with human epidermal growth factor receptor 2.
评估激素(雌激素受体α、雌激素受体β、孕激素受体)和生长因子受体(胰岛素样生长因子受体、人表皮生长因子受体2)表达与子宫癌肉瘤疾病进展的关系。
采用标准方法对组织芯片进行免疫组织化学检测。通过Wilcoxon秩和检验评估组间差异。通过线性趋势分析确定肿瘤分期与受体表达之间的相互作用。
与正常子宫内膜相比,癌肉瘤中雌激素受体α和孕激素受体表达较低(均P <.01),但雌激素受体β过表达(P =.02)。雌激素受体β表达在疾病晚期增加(P =.02)。与正常子宫内膜相比,癌肉瘤中胰岛素样生长因子受体表达较低(P =.01)。人表皮生长因子受体2表达升高,并随疾病进展而增加(P <.01)。
在子宫癌肉瘤中,雌激素受体β表达升高并随疾病进展而增加,而雌激素受体α和孕激素受体受到抑制。人表皮生长因子受体2表达增加,而胰岛素样生长因子受体低于正常子宫内膜。这些数据支持雌激素受体β通过与人表皮生长因子受体2相互作用在疾病进展中发挥潜在作用。